Navigation Links
Genyous Biomed Announces Private Placement Financing
Date:1/29/2009

Company will leverage multivalent drug development platform, expand oncology pipeline, and explore potential for other chronic diseases

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Genyous Biomed International Inc. ("Genyous") announced today that it has entered into a $36 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $12 million before March 31, 2009, $12 million before December 31, 2009 and $12 million before December 31, 2010. Genyous anticipates that these funds will cover operations for three years. "This financing will enable us to further develop our oncology pipeline," said James Dao, Chairman & CEO of Genyous. "In addition, we will be able to leverage our MFMT(TM) drug development platform and extend into other chronic diseases of interest which include BPH, COPD, pain and CNS," said Mr. Dao.

MFMT(TM) drugs, a Genyous innovation, possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases. These multivalent therapies were designed using a systems biology strategy that takes into consideration crosstalk between cells, their microenvironment and the host organism (e.g. the immune system response). The comprehensive therapeutic activity profile of MFMT(TM) drugs represents an opportunity to significantly improve outcomes. By possessing multiple therapeutic functions and working through a multiplicity of biological targets, relatively low and well-tolerated doses of therapeutic actives are sufficient to treat diseases while minimizing disruption of and restoring the body's homeostasis. This unique characteristic of MFMT(TM) drug candidates leads to less risk of toxicity, side effects and development of drug resistance.

Chronic diseases are now at the center of America's healthcare crisis. According to the U.S. Centers for Disease Control and Prevention, an estimated 133 million people (more than one in three Americans), live with at least one chronic condition and the number continues to grow rapidly. Seventy-five percent of the $2.1 trillion spent on healthcare in the U.S. goes to treating people who suffer from chronic conditions. However, the efficacy and safety of these therapies for chronic diseases has not improved significantly for the past 50 years. For example the cancer mortality rate in the U.S. has only decreased by 5 percent since 1950.

About Genyous Biomed International Inc.

Genyous Biomed International Inc., www.genyous.com, was founded in 2000 to find new solutions for treating chronic diseases. The Company has developed the novel Multifunctional Multitargeted (MFMT(TM)) drug development platform to create multivalent drugs designed to address the heterogeneous nature of chronic diseases. Our lead drug candidates are poised for clinical trials in numerous therapeutic areas including cancer, pain, CNS and pre-cancerous indications such as BPH and COPD.


'/>"/>
SOURCE Genyous Biomed International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
2. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
3. BioMed Realty Trusts Center for Life Science Boston Now 91% Leased
4. BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
5. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
7. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
8. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
9. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
10. Response Biomedical Corporation Announces Change of Executives
11. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... ... to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is making ... app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of his ... says, “The positive response to the Snapchat videos we started last month has been overwhelming. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery Center, Washington ... opening a brand new child and adolescent residential treatment center on June 1. ... even more specialized eating disorder treatment and access to life-saving care. , To ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)... Florida , May 25, 2016 ... Conference & Expo earlier this month, the numbers and ... revenues continue to climb into the billions, more research ... newly released 4th Edition State of Legal Marijuana Markets ... a cannabis-focused data-analysis firm, much of the increase in ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology: